pivotal 1 study of abbv-rgx-314 (also known as rgx-314) gene therapy administered via subretinal delivery one time in participants with namd

Conditions: AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; Wet AMD; CNV; Neovascular AMD; Neovascular Age-related Macular Degeneration; Choroidal Neovascularization

Summary: abbv-rgx-314 (also known as rgx-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet amd or namd). wet amd is characterized by loss of vision due to new, leaky blood vessel formation in the retina. wet amd is a significant cause of vision loss in the united states, europe and japan, with up to 2 million people living with wet amd in these geographies alone. current anti-vascular endothelial growth factor (anti-vegf) therapies have significantly changed the landscape for treatment of wet amd, becoming the standard of care due to their ability to maintain or prevent progression of vision loss in the majority of patients. these therapies, however, require life-long intraocular injections, typically repeated every 4 to 16 weeks in frequency, to maintain efficacy. due to the burden of these treatments, patients often experience a decline in vision with reduced frequency of treatment over time.

this randomized, partially masked, active-controlled, phase 2b/3 clinical study will evaluate the efficacy and safety of abbv-rgx-314 gene therapy in participants with namd. the study will evaluate 2 dose levels of abbv-rgx-314 relative to an active comparator. the primary endpoint of this study is the mean change from baseline in best-corrected visual acuity (bcva) of abbv-rgx-314 relative to ranibizumab at week 54. approximately 540 participants who meet the inclusion/exclusion criteria, will be enrolled into one of 3 arms.

Eligibility criteria:
inclusion criteria: 1. age ≥ 50 years and ≤ 89 years 2. an etdrs bcva letter score between ≤ 78 and ≥ 40 in the study eye 3. diagnosis of subfoveal cnv secondary to amd in the study eye previously treated with anti-vegf 4. must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye. 5. willing and able to provide written, signed informed consent for this study 6. participants must have demonstrated a meaningful response to anti-vegf therapy at study entry exclusion criteria: 1. cnv or macular edema in the study eye secondary to any causes other than amd 2. subfoveal fibrosis or atrophy in the study eye, as determined by crc 3. any condition in the investigator's opinion that could limit va improvement in the study eye 4. active or history of retinal detachment, or current retinal tear that cannot be treated, in the study eye 5. advanced glaucoma or history of secondary glaucoma in the study eye 6. history of intraocular surgery in the study eye within 12 weeks prior to randomization 7. history of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational product, other than anti-vegf therapy, in the 6 months prior to screening visit 1 8. prior treatment with gene therapy 9. recent myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months

Keywords: age-related macular degeneration neovascular age-related macular degeneration macular degeneration wet macular degeneration choroidal neovascularization retinal degeneration retinal diseases eye diseases ranibizumab angiogenesis inhibitors angiogenesis modulating agents growth substances physiological effects of drugs growth inhibitors antineoplastic agents gene therapy anti-vascular endothelial grown factory therapy anti-vegf therapy